Sample size estimation (SSE) is an important issue in the planning of clinical studies. While larger studies are likely to have sufficient power, it may be unethical to expose more patients than necessary to answer a scientific question. Budget considerations may also cause one to limit the study to an adequate size to answer the question at hand. Typically at the planning stage, a statistically based justification for sample size is provided. An effective sample size is usually planned under a pre-specified type I error rate, a desired power under a particular alternative and variability associated with the observations recorded. The nuisance parameter such as the variance is unknown in practice. Thus, information from a preliminary pilot study is often used to estimate the variance. However, calculating the sample size based on the estimated nuisance parameter may not be stable. Sample size re-estimation (SSR) at the interim analysis may provide an opportunity to re-evaluate the uncertainties using accrued data and continue the trial with an updated sample size. This article evaluates a proposed SSR method based on controlling the variability of nuisance parameter. A numerical study is used to assess the performance of proposed method with respect to the control of type I error. The proposed method and concepts could be extended to SSR approaches with respect to other criteria, such as maintaining effect size, achieving conditional power, and reaching a desired reproducibility probability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10543406.2015.1092031 | DOI Listing |
J Public Health (Oxf)
January 2025
Division of Nursing, Midwifery and Social Work, School of Health Sciences, The University of Manchester, Jean McFarlane Building, Oxford Road, Manchester M13 9PL, UK.
Background: As the UK COVID-19 vaccination programme progressed, greater emphasis was placed on the implementation of localized targeted vaccination activities to address inequalities in vaccination coverage. This study examines one UK region's approach to the delivery of targeted vaccination activities and identifies key factors influencing implementation.
Methods: Qualitative interviews were conducted with a purposive sample of key individuals involved in vaccination delivery across Greater Manchester (GM).
BMJ Open
January 2025
Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Background: The avoidable causes of infant mortality should be identified, and interventions should be made to improve the infant mortality rate. The cause of infant deaths should be assessed in both medical and social contexts.
Objectives: We aimed to determine the medical causes of infant mortality by verbal autopsy and its determinants in two rural blocks of the Khordha district of Odisha and assess the pathway of care and delay in seeking care for the illness preceding infant death using the three-delay model.
Am J Obstet Gynecol MFM
January 2025
Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil.
Background: Preeclampsia is a major hypertensive disorder of pregnancy, which may lead to severe complications, particularly in the first two weeks of the postpartum period. During the postpartum period, blood pressure levels remain high, often increasing to levels higher than those experienced during pregnancy. Furosemide, a fast-acting diuretic, reduces the intravascular volume overload and may represent an alternative to accelerate the normalization of blood pressure levels.
View Article and Find Full Text PDFJ Stomatol Oral Maxillofac Surg
January 2025
Department of Prosthodontics and Gerostomatology, Poznan University of Medical Sciences, 60-792 Poznan, Poland.
Background: Tooth agenesis, particularly the absence of upper lateral incisors, presents substantial challenges for clinicians due to the associated bone atrophy, which limits the use of traditional implant solutions. Current options, such as endosseous implants combined with guided bone regeneration (GBR), often fail due to insufficient osseointegration in atrophic bone. This study aims to evaluate the effectiveness of custom-made, additively manufactured subperiosteal implants in addressing these challenges METHODS: This retrospective study assessed 16 custom-made subperiosteal implants used in 12 patients (10 females, 2 males; mean age 25 ± 2.
View Article and Find Full Text PDFAm Heart J
January 2025
Department of Cardiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.
Rationale: The biodegradable polymer BioMatrix Alpha™ stent contains biolimus A9 drug which is sirolimus derivative increase in lipophicity. The biodegradable polymer sirolimus eluting Combo™ stent is a dual-therapy sirolimus-eluting and CD34+ antobody coated stent capturing endothelial progenitor cells (EPCs).
Hypothesis: The main hypothesis of the SORT OUT XI trial was that the biodegradable polymer biolimus A9 BioMatrix Alpha ™ stent is noninferior to the biodegradable polymer sirolimus eluting Combo™ stent in an all-comers population with coronary artery disease undergoing percutaneous coronary intervention (PCI).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!